{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:43:03Z","timestamp":1760204583763},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,3,22]],"date-time":"2012-03-22T00:00:00Z","timestamp":1332374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research Pt B"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:p>Lersivirine is a second\u2010generation nonnucleoside reverse transcriptase inhibitor undergoing clinical development for the treatment of <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>\u20101. An embryo\u2013fetal developmental toxicity study was performed to evaluate the maternal and developmental toxicity of lersivirine in pregnant mice. Mated Crl:<jats:styled-content style=\"fixed-case\">CD1(ICR<\/jats:styled-content>) mice were administered 0, 150, 350, and 500 mg\/kg lersivirine once daily by oral gavage on gestation days 6 to 17, followed by cesarean section on gestation day 18. The first 2 days of dosing for the high\u2010dose group were done at 250 mg\/kg to allow induction of hepatic metabolizing enzymes, after which the dose was increased to 500 mg\/kg\/day. This dosing paradigm allowed for maintenance of exposure in the high\u2010dose group despite the considerable autoinduction that occurs in rodents following lersivirine treatment. Lersivirine did not cause an increase in external, visceral, or skeletal malformations. Intrauterine growth retardation, demonstrated by reduced fetal body weights and increased variations associated with delayed skeletal ossification, was noted at 350 and 500 mg\/kg\/day. The results of these studies indicate that lersivirine is not teratogenic in mice.<\/jats:p>","DOI":"10.1002\/bdrb.21008","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T11:25:08Z","timestamp":1332501908000},"page":"225-230","source":"Crossref","is-referenced-by-count":2,"title":["Developmental Toxicity Study of Lersivirine in Mice"],"prefix":"10.1002","volume":"95","author":[{"given":"Gregg D.","family":"Cappon","sequence":"first","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Bowman","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah N.","family":"Campion","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Chmielewski","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Hurtt","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory L.","family":"Finch","sequence":"additional","affiliation":[{"name":"Drug Safety Research and Development Pfizer Worldwide Research &amp; Development  Groton CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise M.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Charles River Laboratories Preclinical Services  Horsham PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,22]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250802069088"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21014"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01455-09"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.10.007"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.09.008"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981645"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1955.10501294"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2307\/2528490"},{"key":"e_1_2_5_11_1","first-page":"96","volume-title":"Statistical methods for research workers","author":"Fisher RA.","year":"1950"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02981671"},{"key":"e_1_2_5_13_1","unstructured":"Institute of Laboratory Animal Research Commission on Life Sciences National Research Council. 1996. Guide for the Care and Use of Laboratory Animals. The National Academies Press. Washington D.C."},{"key":"e_1_2_5_14_1","unstructured":"Lewis\u2010HallFC.2005.Important information about sustiva (efavirenz) and pregnancy. Available at:http:\/\/www.fda.gov\/ForConsumers\/ByAudience\/ForPatientAdvocates\/HIVandAIDSActivities\/ucm124885.htm."},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/1811147a0"},{"issue":"2","key":"e_1_2_5_16_1","first-page":"17","article-title":"Efavirenz reclassified as FDA pregnancy category D","volume":"17","author":"Mofenson LM.","year":"2005","journal-title":"AIDS Clin Care"},{"key":"e_1_2_5_17_1","first-page":"258","volume-title":"Statistical methods","author":"Snedecor GW","year":"1967"},{"key":"e_1_2_5_18_1","first-page":"388","volume-title":"Kruskal\u2010Wallis test biometry: the principles and practice of statistics in biological research","author":"Sokal RR","year":"1969"},{"key":"e_1_2_5_19_1","first-page":"61","article-title":"Refinements in rapid clearing technic in the KOH alizarin red S method for fetal bone","volume":"39","author":"Staples RE","year":"1964","journal-title":"Stain Technol"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.584062"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250902903079"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.05.061"},{"key":"e_1_2_5_23_1","first-page":"262","volume-title":"Methods for administering agents and detecting malformations in experimental animals. Teratology: principles and techniques","author":"Wilson JG.","year":"1965"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199704)55:4<249::AID-TERA5>3.0.CO;2-W"}],"container-title":["Birth Defects Research Part B: Developmental and Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdrb.21008","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdrb.21008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:34:36Z","timestamp":1700555676000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdrb.21008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1002\/bdrb.21008"],"URL":"https:\/\/doi.org\/10.1002\/bdrb.21008","archive":["Portico"],"relation":{},"ISSN":["1542-9733","1542-9741"],"issn-type":[{"value":"1542-9733","type":"print"},{"value":"1542-9741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,22]]}}}